AU2021360114A1 - Opicapone and levodopa for the treatment of parkinson's disease - Google Patents

Opicapone and levodopa for the treatment of parkinson's disease Download PDF

Info

Publication number
AU2021360114A1
AU2021360114A1 AU2021360114A AU2021360114A AU2021360114A1 AU 2021360114 A1 AU2021360114 A1 AU 2021360114A1 AU 2021360114 A AU2021360114 A AU 2021360114A AU 2021360114 A AU2021360114 A AU 2021360114A AU 2021360114 A1 AU2021360114 A1 AU 2021360114A1
Authority
AU
Australia
Prior art keywords
levodopa
opicapone
combination
pharmaceutically acceptable
unpredictable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021360114A
Other languages
English (en)
Other versions
AU2021360114A9 (en
Inventor
José Francisco DA COSTA DE PINHO ROCHA
Patricio Manuel Vieira Araújo Soares Da Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of AU2021360114A1 publication Critical patent/AU2021360114A1/en
Publication of AU2021360114A9 publication Critical patent/AU2021360114A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021360114A 2020-10-16 2021-10-14 Opicapone and levodopa for the treatment of parkinson's disease Pending AU2021360114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2016425.7A GB202016425D0 (en) 2020-10-16 2020-10-16 Treatment regimens for parkinson's disease
GB2016425.7 2020-10-16
PCT/PT2021/050036 WO2022081033A1 (en) 2020-10-16 2021-10-14 Opicapone and levodopa for the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
AU2021360114A1 true AU2021360114A1 (en) 2023-06-08
AU2021360114A9 AU2021360114A9 (en) 2024-10-17

Family

ID=73598546

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021360114A Pending AU2021360114A1 (en) 2020-10-16 2021-10-14 Opicapone and levodopa for the treatment of parkinson's disease

Country Status (8)

Country Link
US (1) US20230398105A1 (https=)
EP (1) EP4228618A1 (https=)
JP (1) JP2023546140A (https=)
KR (1) KR20230088753A (https=)
CN (1) CN116490171A (https=)
AU (1) AU2021360114A1 (https=)
GB (1) GB202016425D0 (https=)
WO (1) WO2022081033A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072886A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
EP4262798A1 (en) * 2020-12-17 2023-10-25 Bial-Portela & CA, S.A. Treatment regimens for early idiopathic parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009116882A1 (en) 2008-03-17 2009-09-24 Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
PT2413912T (pt) 2009-04-01 2019-06-11 Bial Portela & Ca Sa Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
BRPI1016132B8 (pt) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP6456143B2 (ja) 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
PT3341380T (pt) * 2015-08-27 2019-12-19 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa
MX383906B (es) * 2015-10-09 2025-03-14 Teva Pharmaceuticals Int Gmbh Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
JP2020023540A (ja) * 2019-10-11 2020-02-13 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Also Published As

Publication number Publication date
US20230398105A1 (en) 2023-12-14
WO2022081033A1 (en) 2022-04-21
CN116490171A (zh) 2023-07-25
GB202016425D0 (en) 2020-12-02
KR20230088753A (ko) 2023-06-20
AU2021360114A9 (en) 2024-10-17
JP2023546140A (ja) 2023-11-01
EP4228618A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
US20250275934A1 (en) Medicaments for slowing parkinson's disease
US20240165104A1 (en) Treatment of depression
Fox et al. The movement disorder society evidence‐based medicine review update: Treatments for the motor symptoms of Parkinson's disease
US20230398105A1 (en) Treatment regimens for parkinson's disease
Pahwa et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose
JP2021080286A (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
Di Rosa et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease
KR20230118933A (ko) 초기 특발성 파킨슨병에 대한 치료 요법
US11439613B2 (en) Levodopa fractionated dose composition and use
Oertel et al. Early (uncomplicated) Parkinson’s disease
US7915262B2 (en) Combination preparations comprising SLV308 and a dopamine agonist
US20260053782A1 (en) Treatment regimens for parkinson's disease
Musey et al. Medical therapies for motor symptoms in Parkinson’s Disease
Citrome et al. 169 Dasotraline for Treatment of Adults with Binge-Eating Disorder: Effect on Binge-related Obsessions and Compulsions
Truong et al. Parkinson's disease
WO2007144421A1 (en) Combination preparations comprising slv308 and a l-dopa
WO2024214102A1 (en) Methods and compositions for reducing symptoms of parkinson's disease
Reichmann et al. NEW DEVELOPMENTS FOR PARKINSON’S THERAPY WITH COMT INHIBITORS
Wolters Conventional Pharmacotherapy in ParkinsonTs Disease
Waters Pharmacologic management of Parkinson disease: Treatment of levodopa-associated" wearing off"
Tankosic Parkinson's disease: new dopaminergic delivery but neuroprotection remains elusive
Katzenschlager of Parkinson’s Disease

Legal Events

Date Code Title Description
SREP Specification republished